Earnings Preview: Aquestive Therapeutics

Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.36.

Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here’s what investors need to know before the announcement.

Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.36.

Aquestive Therapeutics bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.09, which was followed by a 3.65% increase in the share price the next day.

Here’s a look at Aquestive Therapeutics’s past performance and the resulting price change:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -0.41 -0.47 -0.45 -0.44
EPS Actual -0.32 -0.38 -0.37 -0.33
Price Change % 3.65% -0.71% 10.07% 13.23%

eps graph

Stock Performance

Shares of Aquestive Therapeutics were trading at $0.822 as of July 29. Over the last 52-week period, shares are down 74.18%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

To track all earnings releases for Aquestive Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

cbdMD Reports YoY Dip In Q1 Net Sales, Shrinks Operating Loss, Expands Into Hemp And Mushroom Products Markets

Medical cannabis company cbdMD has reported financial results for its first quarter of fiscal 2024. Operating loss improved to $1.1m compared to $4.1m for the same period in the previous year. Gross profit was flat at around $3.5m, while operating expenses were $4.6m, down from $7.6m in the previous year. Total net sales declined to $5.37m from almost $6m in the corresponding prior-year period. Direct-to-consumer net sales represented 82.3% of total net sales, a decrease from 90% in Q1 2023. On 31 December 2023, cbdMD had total working capital of roughly $1.4m compared to approximately $3.4m on 30 September, with cash on hand dropping to roughly $1.5m from $1.8m over the same period. The Charlotte-based company recently struck a securities purchase agreement with five institutional investors to fund the national rollout of its ATRx Labs functional mushroom products, as well as launching the hempMD and ATRx Labs brands.

YCBD